Copenhagen, Denmark – December 28, 2016: IO Biotech today announced successful closure of the €8.5 million second tranche series A investment round. Participants were existing investors Lundbeckfonden and Novo Seeds plus new investor Sunstone Capital.
Copenhagen, Denmark – November 9, 2016: Professor Mads Hald Andersen, CSO of IO Biotech and Director of CCIT (Center for Cancer Immune Therapy) at University of Copenhagen Herlev Hospital in Denmark, will be speaking at the SITC Conference in Maryland this week.
Copenhagen, Denmark – October 4, 2016: IO Biotech today announced that industry veteran Dr Peter Hirth will succeed Dr Hans Schambye as Chairman of the Board of Directors. IO Biotech develops novel therapeutic immuno-oncology vaccines targeting immune check point inhibitory targets to treat cancer.